Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis

Company Overview

Titan Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics based on its ProNeura long‐term, continuous drug delivery platform. Headquartered in South San Francisco, California, the company seeks to enhance patient outcomes through sustained‐release implants designed to deliver medication over extended periods. Titan’s platform is engineered to maintain consistent drug levels while reducing dosing frequency, with the goal of improving compliance and minimizing side effects often associated with conventional dosing schedules.

The company’s lead product, Probuphine®, is a buprenorphine implant approved by the U.S. Food and Drug Administration in 2016 for maintenance treatment of opioid dependence. Probuphine delivers six months of continuous buprenorphine therapy via a small subdermal implant, offering an alternative to daily oral dosages. Titan originally commercialized Probuphine through a partnership with a specialty pharmaceutical company, and it continues to explore strategic collaborations to expand patient access within the United States and potential markets overseas.

In addition to its marketed product, Titan maintains a pipeline of development programs aimed at addressing central nervous system disorders. Research efforts include next‐generation implants for migraine prophylaxis and psychiatric indications such as schizophrenia. The company’s leadership team, led by President and Chief Executive Officer Sunil Bhonsle, combines expertise in drug delivery technology and biopharmaceutical development. Titan Pharmaceuticals remains committed to advancing its ProNeura platform to bring long‐acting implant therapies to patients with chronic and complex conditions.

Key Stats

• Today's Range: $4.55 to $4.80
• 50-Day Range: $3.64 to $5.93
• 52-Week Range: $3.03 to $5.76
• Volume: 3.10 million shs
• Average Volume: 182,557 shs
• Market Capitalization: $7.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Titan Pharmaceuticals Stock Analysis - MarketRank™

Titan Pharmaceuticals scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Titan Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Titan Pharmaceuticals is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Titan Pharmaceuticals is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Titan Pharmaceuticals has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.74% of the float of Titan Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Titan Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Titan Pharmaceuticals has recently decreased by 39.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Titan Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Titan Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.74% of the float of Titan Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Titan Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Titan Pharmaceuticals has recently decreased by 39.69%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.36

News Sentiment

Titan Pharmaceuticals has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Titan Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for TTNP on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Titan Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.72% of the stock of Titan Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 31.49% of the stock of Titan Pharmaceuticals is held by institutions.

TTNP Stock Analysis - Frequently Asked Questions

How have TTNP shares performed this year?

Titan Pharmaceuticals' stock was trading at $3.26 at the start of the year. Since then, TTNP stock has increased by 81.7% and is now trading at $5.9250.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced its quarterly earnings results on Thursday, August, 14th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter.

When did Titan Pharmaceuticals' stock split?

Shares of Titan Pharmaceuticals reverse split on the morning of Tuesday, January 9th 2024.The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Titan Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Titan Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TTNP
• CIK: 910267
• Web: www.titanpharm.com
• Phone: (650) 244-4990
• Fax: 650-244-4956
• Employees: 10
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($2.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.71 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -108.60%
• Return on Assets: -95.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.60
• Quick Ratio: 11.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.67 per share
• Price / Book: 2.22

Miscellaneous

• Outstanding Shares: 1,330,000
• Free Float: 1,320,000
• Market Cap: $7.88 million
• Optionable: Optionable
• Beta: 1.37